Mersana Stock Story

MRSN -  USA Stock  

USD 9.61  0.02  0.21%

In general, we focus on analyzing Mersana (NASDAQ:MRSN) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mersana Therapeutics daily price indicators and compare them against related drivers. While this unique economic environment continues, Mersana Therapeutics may throw investors more surprises next month. What exactly are Mersana Therapeutics shareholders getting in October?
Published over a week ago
View all stories for Mersana Therapeutics | View All Stories
Volatility may be your only friend when it comes to investing in Mersana Therapeutics
We provide investment recommendation to complement the last-minute expert consensus on Mersana Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
About 102.0% of the company shares are owned by institutional investors. The book value of Mersana Therapeutics was now reported as 2.87. The company recorded a loss per share of 1.59. Mersana Therapeutics had not issued any dividends in recent years.
The successful prediction of Mersana Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mersana Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Mersana Therapeutics based on Mersana Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Mersana Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mersana Therapeutics's related companies.

Use Technical Analysis to project Mersana expected Price

Mersana Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Mersana Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Mersana Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Mersana utilizes its cash?

To perform a cash flow analysis of Mersana Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Mersana Therapeutics is receiving and how much cash it distributes out in a given period. The Mersana Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Mersana Therapeutics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (76.66 Million)

Exercise or conversion by Timothy Lowinger of 2216 shares of Mersana Therapeutics subject to Rule 16b-3

Legal trades by Mersana Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Mersana insider trading alert for exercise of stock option (right to buy) by Timothy Lowinger, Chief Science & Tech. Officer, on 24th of August 2021. This event was filed by Mersana Therapeutics Inc with SEC on 2021-08-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another Deeper Perspective

Mersana Therapeutics reported the previous year's revenue of 828 K. Net Loss for the year was (105.81 M) with loss before overhead, payroll, taxes, and interest of (66.21 M).
 2020 2021 (projected)
Interest Expense359 K360.61 K
Gross Profit828 K849.79 K

Deferred Revenue Breakdown

Mersana Therapeutics Deferred Revenue yearly trend continues to be quite stable with very little volatility. Deferred Revenue may rise above about 4.1 M this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Mersana Therapeutics Deferred Revenue is quite stable at the moment as compared to the past year. The company's current value of Deferred Revenue is estimated at 4.09 Million
201017.12 Million
201660.3 Million
201750.41 Million
201846.2 Million
20194.82 Million
20203.99 Million
20214.09 Million

Our perspective of the latest Mersana Therapeutics rise

Latest market risk adjusted performance indicator falls down to -0.18. Possible price upswing? Mersana Therapeutics exhibits very low volatility with skewness of -4.06 and kurtosis of 28.3. However, we advise investors to further study Mersana Therapeutics technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Mersana Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Mersana Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Whereas other entities in the biotechnology industry are either recovering or due for a correction, Mersana Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 13th of September 2021, we see that Mersana Therapeutics hyperactively responds to market trends. The company is undervalued with very low probability of distress within the next 24 months. Our concluding 90 days buy vs. sell advice on the company is Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Mersana Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to